David K Simon

List of Publications by Year in Descending Order

74 papers	5,373 citations	34 h-index	73 g-index
76 ext. papers	6,252 ext. citations	6.9 avg, IF	5.32 L-index

#	Paper	IF	Citations
74	Associations between exercise classes and self-reported exercise by people with Parkinson's disease at Parkinson's foundation centers of excellence.. *Clinical Parkinsonism & Related Disorders*, **2022**, 6, 100137	0.9	
73	Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. *JAMA Neurology*, **2021**, 78, 312-320	17.2	34
72	A New Approach to the Development of Disease-Modifying Therapies for PD. *Movement Disorders*, **2021**, 36, 1281	7	
71	Differences in the Presentation and Progression of Parkinson's Disease by Sex. *Movement Disorders* , **2021**, 36, 106-117	7	16
70	The Relationship Between Olfactory Dysfunction and Constipation in Early Parkinson's Disease. *Movement Disorders*, **2021**, 36, 781-782	7	1
69	Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2021**, 326, 926-939	27.4	16
68	Acute readmission following deep brain stimulation surgery for Parkinson's disease: A nationwide analysis. *Parkinsonism and Related Disorders*, **2020**, 70, 96-102	3.6	3
67	Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. *Clinics in Geriatric Medicine*, **2020**, 36, 1-12	3.8	143
66	VPS35 and the mitochondria: Connecting the dots in Parkinson's disease pathophysiology. *Neurobiology of Disease*, **2020**, 145, 105056	7.5	9
65	Boxing Exercises as Therapy for Parkinson Disease. *Topics in Geriatric Rehabilitation*, **2020**, 36, 160-165	0.7	3
64	Altered muscle electrical tissue properties in a mouse model of premature aging. *Muscle and Nerve*, **2019**, 60, 801-810	3.4	6
63	Genetic risk of Parkinson disease and progression:: An analysis of 13 longitudinal cohorts. *Neurology: Genetics*, **2019**, 5, e348	3.8	57
62	Transportation innovation to aid Parkinson disease trial recruitment. *Contemporary Clinical Trials Communications*, **2019**, 16, 100449	1.8	4
61	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. *Neurology*, **2019**, 92, 329-337	6.5	144
60	Efficacy of Deep Brain Stimulation in a Patient with Genetically Confirmed Chorea-Acanthocytosis. *Case Reports in Neurology*, **2019**, 11, 199-204	1	2
59	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. *Movement Disorders*, **2019**, 34, 1839-1850	7	69
58	Inverse probability weighted Cox regression for doubly truncated data. *Biometrics*, **2018**, 74, 481-487	1.8	13

57	Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. *Movement Disorders*, **2017**, 32, 319-324	7	111
56	Caffeine, creatine, GRIN2A and Parkinson's disease progression. *Journal of the Neurological Sciences* , **2017**, 375, 355-359	3.2	17
55	Autonomic and electrocardiographic findings in Parkinson's disease. *Autonomic Neuroscience: Basic and Clinical*, **2017**, 205, 93-98	2.4	11
54	Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. *Journal of the Neurological Sciences*, **2017**, 377, 137-143	3.2	19
53	Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores. *Neurology*, **2017**, 89, 1789-1794	6.5	15
52	Mitochondrial DNA mutations in Parkinson's disease brain. *Acta Neuropathologica Communications*, **2017**, 5, 33	7.3	7
51	Clinical Impact of 123I-Ioflupane SPECT (DaTscan) in a Movement Disorder Center. *Neurodegenerative Diseases*, **2017**, 17, 38-43	2.3	8
50	Head injury at early ages is associated with risk of Parkinson's disease. *Parkinsonism and Related Disorders*, **2016**, 23, 57-61	3.6	33
49	Complicated spontaneous intracranial hypotension treated with intrathecal saline infusion. *Practical Neurology*, **2016**, 16, 146-9	2.4	8
48	Metabolomic analysis of exercise effects in the POLG mitochondrial DNA mutator mouse brain. *Neurobiology of Aging*, **2015**, 36, 2972-2983	5.6	23
47	Peripheral Biomarkers of Parkinson's Disease Progression and Pioglitazone Effects. *Journal of Parkinsonıs Disease*, **2015**, 5, 731-6	5.3	20
46	Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. *JAMA - Journal of the American Medical Association*, **2015**, 313, 584-93	27.4	153
45	Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. *Clinical Neuropharmacology*, **2015**, 38, 163-9	1.4	18
44	Somatic mitochondrial DNA mutations do not increase neuronal vulnerability to MPTP in young POLG mutator mice. *Neurotoxicology and Teratology*, **2014**, 46, 62-7	3.9	11
43	Rapamycin drives selection against a pathogenic heteroplasmic mitochondrial DNA mutation. *Human Molecular Genetics*, **2014**, 23, 637-47	5.6	63
42	A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. *JAMA Neurology*, **2014**, 71, 543-52	17.2	239
41	Computationally simple estimation and improved efficiency for special cases of double truncation. *Lifetime Data Analysis*, **2014**, 20, 335-54	1.3	8
40	No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial. *PLoS ONE*, **2014**, 9, e112287	3.7	9

39	The inverse association of cancer and Alzheimer's: a bioenergetic mechanism. *Journal of the Royal Society Interface*, **2013**, 10, 20130006	4.1	38
38	Behavioral and metabolic characterization of heterozygous and homozygous POLG mutator mice. *Mitochondrion*, **2013**, 13, 282-91	4.9	23
37	Genetic risk factors in Parkinson's disease: single gene effects and interactions of genotypes. *Journal of Neurology*, **2012**, 259, 2503-5	5.5	6
36	An inverse-Warburg effect and the origin of Alzheimer's disease. *Biogerontology*, **2012**, 13, 583-94	4.5	59
35	The utility of laser-generated visual-cueing in Parkinsonian patients with gait freezing. *Parkinsonism and Related Disorders*, **2012**, 18, 401	3.6	
34	Singing in groups for Parkinson's disease (SING-PD): a pilot study of group singing therapy for PD-related voice/speech disorders. *Parkinsonism and Related Disorders*, **2012**, 18, 548-52	3.6	36
33	Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. *Annals of Neurology*, **2012** , 71, 370-84	9.4	214
32	Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. *Annals of Neurology*, **2012**, 71, 850-4	9.4	79
31	Frequency of the D620N mutation in VPS35 in Parkinson disease. *Archives of Neurology*, **2012**, 69, 1360-4		66
30	Pgc-1overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf. *PLoS ONE*, **2012**, 7, e48925	3.7	52
29	Mitochondria and Parkinson's disease. *Parkinsonıs Disease*, **2011**, 2011, 261791	2.6	2
28	Do somatic mitochondrial DNA mutations contribute to Parkinson's disease?. *Parkinsonıs Disease*, **2011**, 2011, 659694	2.6	10
27	The c.-237_236GA>TT THAP1 sequence variant does not increase risk for primary dystonia. *Movement Disorders*, **2011**, 26, 549-52	7	15
26	Association of cumulative lead exposure with Parkinson's disease. *Environmental Health Perspectives*, **2010**, 118, 1609-13	8.4	97
25	MELAS syndrome, cardiomyopathy, rhabdomyolysis, and autism associated with the A3260G mitochondrial DNA mutation. *Biochemical and Biophysical Research Communications*, **2010**, 402, 443-7	3.4	19
24	Maternal inheritance and mitochondrial DNA variants in familial Parkinson's disease. *BMC Medical Genetics*, **2010**, 11, 53	2.1	26
23	Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. *PLoS ONE*, **2010**, 5, e12333	3.7	80
22	Do mtDNA deletions drive premature aging in mtDNA mutator mice?. *Aging Cell*, **2009**, 8, 502-6	9.9	37

21	Transcribe to survive: transcriptional control of antioxidant defense programs for neuroprotection in Parkinson's disease. *Antioxidants and Redox Signaling*, **2009**, 11, 509-28	8.4	77
20	Caffeine and progression of Parkinson disease. *Clinical Neuropharmacology*, **2008**, 31, 189-96	1.4	30
19	Noninvasive brain stimulation for Parkinson's disease and dystonia. *Neurotherapeutics*, **2008**, 5, 345-61	6.4	103
18	Mitochondrial complex I gene variant associated with early age at onset in spinocerebellar ataxia type 2. *Archives of Neurology*, **2007**, 64, 1042-4		29
17	Dystonia. *New England Journal of Medicine*, **2006**, 355, 818-29	59.2	205
16	Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. *Cell*, **2006**, 127, 397-408	56.2	1689
15	Somatic mitochondrial DNA mutations in single neurons and glia. *Neurobiology of Aging*, **2005**, 26, 1343-55	5.6	69
14	Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival. *Journal of Biological Chemistry*, **2005**, 280, 40398-401	5.4	155
13	Mistaken diagnosis of psychogenic gait disorder in a man with status cataplecticus ("limp man syndrome"). *Movement Disorders*, **2004**, 19, 838-840	7	15
12	Attenuation of free radical production and paracrystalline inclusions by creatine supplementation in a patient with a novel cytochrome b mutation. *Muscle and Nerve*, **2004**, 29, 537-47	3.4	41
11	Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. *Neurobiology of Aging*, **2004**, 25, 71-81	5.6	95
10	A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease. *Archives of Neurology*, **2003**, 60, 722-5		79
9	A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia. *Neurogenetics*, **2003**, 4, 199-205	3	32
8	High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. *Human Molecular Genetics*, **2002**, 11, 133-45	5.6	262
7	A frameshift mitochondrial complex I gene mutation in a patient with dystonia and cataracts: is the mutation pathogenic?. *Journal of Medical Genetics*, **2001**, 38, 58-61	5.8	7
6	Plasticity in the development of topographic order in the mammalian retinocollicular projection. *Developmental Biology*, **1994**, 162, 384-93	3.1	47
5	Responses of retinal axons in vivo and in vitro to position-encoding molecules in the embryonic superior colliculus. *Neuron*, **1992**, 9, 977-89	13.9	90
4	Influence of position along the medial-lateral axis of the superior colliculus on the topographic targeting and survival of retinal axons. *Developmental Brain Research*, **1992**, 69, 167-72		40

3	Relationship of retinotopic ordering of axons in the optic pathway to the formation of visual maps in central targets. *Journal of Comparative Neurology*, **1991**, 307, 393-404	3.4	62
2	Limited topographic specificity in the targeting and branching of mammalian retinal axons. *Developmental Biology*, **1990**, 137, 125-34	3.1	87
1	Nilotinib in Patients with Advanced Parkinson Disease: A Randomized Phase 2A Study (NILO-PD)		6